SECO and Nayax Announce Plans for Strategic Partnership to Offer IoT-Integrated Payment Solutions for OEMs
SECO
HERZLIYA, Israel and AREZZO, Italy, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, and SECO S.p.A. (IOT.MI), a leading provider of end-to-end technological solutions for industrial digitalization, today announced the execution of a Memorandum of Understanding, ('MOU'), with the intention to establish a long-term strategic partnership to embed Nayax-powered payments directly within SECO products, starting with a payment-enabled smart screen designed as a convenient all-in-one solution for the next generation of intelligent vending machines, micro markets, smart coolers, and automated self-service retail machines.
Together, Nayax and SECO plan to deliver comprehensive, fully integrated IoT solutions which combine seamless and secure payments with remote machine management and AI-driven business intelligence for any enterprise with automated self-service points of sale. OEMs will gain access to differentiated, cost optimized hardware which contains a combination of SECO's industry-leading IoT capabilities and Nayax's versatile payment platform.
Embedding Nayax's payment infrastructure within SECO's products will also empower businesses to manage their payment flows and automated self-service points of sale through Clea, SECO's end-to-end IoT-AI software platform that securely collects, analyzes, and manages connected device data in real time to enable intelligent automation and cross-functional business insights. Together, Nayax and SECO will offer an unbeatable joint value proposition of lower operational costs, advanced telematics, and flexible integrated payments, built for easy integration by OEMs across their product lineups.
'Our partnership with SECO propels Nayax toward new frontiers in automated self-service retail, harnessing SECO's extensive OEM network to extend our commercial reach into high-demand markets worldwide and accelerate broader adoption of our embedded payment platform,' said Oren Tepper, Chief Commercial Officer of Nayax. 'We're proud to work with SECO to offer game-changing, fully embedded payment solutions which unify telematics, analytics, and frictionless transactions under one umbrella.'
'Partnering with Nayax allows SECO to embed a versatile and powerful global payment platform directly into our connected screens and devices, bolstering our competitive position and delivering exceptional value for our OEM customers across key verticals like vending, coffee, and electric vehicle supply equipment,' said Fausto Di Segni, Head of IoT & AI Europe at SECO. 'We will unite robust IoT management, engaging displays, and embedded payments to streamline deployment and cut costs for OEMs and their end-customers.'
Nayax invites OEMs to visit SECO at booth 320 (hall 1) at the Embedded World Trade Show in Nuremberg from March 11-13 to learn how Nayax and SECO's full suite of solutions can transform business operations and provide a competitive edge.
SECO
SECO (IOT.MI) is a high-tech company that develops and manufactures cutting-edge solutions for the digitalization of industrial products and processes. SECO's hardware and software offerings enable B2B companies to easily introduce edge computing, Internet of Things, data analytics, and artificial intelligence to their businesses. SECO's technology spans across multiple fields of application, serving more than 450 customers across sectors such as medical, industrial automation, fitness, vending, transportation, and many others. Through live monitoring and smart control of in-the-field devices, SECO solutions contribute to low environmental impact business operations via a more efficient use of resources.
For more information: http://www.seco.com/
Contacts
SECO S.p.A.Clarence NahanHead of Corporate Development & Investor RelationsTel. +39 0575 26979investor.relations@seco.com
Nayax
Nayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. With foundations and global leadership in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers' growth across multiple channels. As of September 30, 2024, Nayax has 11 global offices, approximately 1,100 employees, connections to more than 80 merchant acquirers and payment method integrations and globally recognized as a payment facilitator. Nayax's mission is to improve our customers' revenue potential and operational efficiency — effectively and simply. For more information, please visit www.nayax.com.
Nayax Public Relations Contact:
Scott Gamm Strategy Voice Associates Scott@strategyvoiceassociates.com
Nayax Investor Relations Contact:
Aaron Greenberg Chief Strategy Officer IR@nayax.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3fab6cfe-bda4-4924-9bdb-3919f6e92505Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 minutes ago
- Associated Press
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. 'Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks,' said Berndt Modig, Chief Executive Officer of Pharvaris. 'Building on our R&D call from last week, we shared data demonstrating the potential for deucrictibant to address the unmet needs of people living with bradykinin-mediated angioedema beyond HAE-1/2. Deucrictibant showed sustained attack reduction and improved quality of life measures in the randomized portion of the CHAPTER-1 study, which was maintained in the open-label extension study, as well as early-onset symptom relief and complete symptom resolution in a single dose in most attacks in our ongoing RAPIDe-2 on-demand long-term extension RAPIDe-3 is the first and only phase 3 on-demand study that will explore 'end-of-progression' as a new pre-specified endpoint, which is particularly meaningful for people living with HAE. Together with the outcomes from other study endpoints, we will be able to assess the full impact of deucrictibant on an HAE attack from start to end.' Details of the presentations are outlined below: Prophylaxis Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study, a poster presentation by Emel Aygören-Pürsün, M.D. Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study, a flash talk by Markus Magerl, M.D. CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks, a flash talk by William Lumry, M.D. Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone, an oral presentation by Laurence Bouillet, M.D., Ph.D. On-Demand Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study, a thematic poster session by Henriette Farkas, M.D., Ph.D., Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study, a flash talk by Anna Valerieva, M.D., Ph.D. Expansion Beyond HAE Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema, a flash talk by Evangelia Pardali, Ph.D. Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency, a thematic poster session by Andrea Zanichelli, M.D., Ph.D. The posters are available on the Investors section of the Pharvaris website at: About Deucrictibant Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration and orphan designation by the European Commission. About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit Forward Looking Statements This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words 'believe,' 'anticipate,' 'expect,' 'estimate,' 'may,' 'could,' 'should,' 'would,' 'will,' 'intend' and similar expressions. These forward-looking statements are based on management's current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris' actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the outcome and timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; political conditions, such as the current war between Russia and Ukraine; economic conditions, including continuing inflation concerns; and the other factors described under the headings 'Cautionary Statement Regarding Forward-Looking Statements' and 'Item 3. Key Information—D. Risk Factors' in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris' views as of any date subsequent to the date of this press release. Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [email protected]
Associated Press
4 minutes ago
- Associated Press
VEON Announces USD 35 Million Share Buyback
Announcement marks the third phase of USD 100 million share buyback program Dubai, June 16, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator ('VEON' or the 'Company'), announces that it will shortly commence the third phase of its previously announced share buyback program with respect to the Company's American Depositary Shares ('ADSs'). This third phase of the buyback will be in the amount of up to USD 35 million. The third phase of the share buyback program is being launched after the successful completion of the second phase on May 21, 2025. Cumulatively, the two earlier phases of the program have resulted in the repurchase of 1.43 million ADSs at an average repurchase price of USD 45.59 per ADS. VEON had announced a share buyback program of up to USD 100 million on August 1, 2024. The Company continues to believe that its ADSs are undervalued relative to its operational performance and strategic potential. With the buyback program, VEON aims to optimize shareholder value and strengthen its financial position for future opportunities. The buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18. VEON is also considering options to raise external financing through a sub-benchmark private placement of bonds, with a tenor of up to approximately four years (the 'Notes'), with the goal of supporting the Company's strategic initiatives and enhancing its financial flexibility. The Notes, if issued, will be issued by VEON Midco B.V. and guaranteed by VEON Amsterdam B.V. This evaluation is a part of VEON's ongoing capital planning effort and discussions with potential institutional investors are in progress. About VEON VEON is a digital operator that provides connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world's population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ and headquartered in Dubai. For more information visit: No Offer or Solicitation ADS Buyback This press release shall not constitute an offer to buy ADSs nor the solicitation of an offer to sell ADSs. The ADS buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18. Private Placement Transaction This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any person to whom, such an offer, solicitation or sale is unlawful. The offering of Notes described in this press release has not been and will not be registered under U.S. securities laws or the securities laws of any other jurisdiction and, accordingly, the offer or sale of these securities (if any) may be made only in a transaction exempt from the registration requirements of the U.S. Securities Act and any other applicable securities laws. There will be no public offering of the Notes in the United States. The Notes will be offered (if at all) in the European Economic Area and in the UK only to persons who are not retail investors. Forward-Looking Statements This release contains 'forward-looking statements,' as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to the initiation and continuation of the third phase of the Company's share buyback program, the proposed transactions, including any Notes private placement offering, the expected timing of completing the proposed transactions and the expected impact of the proposed transactions. These statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause VEON's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of, or failure to consummate, the ADS buyback or any Notes private placement; the outcome of any legal proceedings that may be instituted against VEON Ltd. or others; and other risks and uncertainties set forth in the Company's and its subsidiaries' filings. Forward-looking statements are inherently subject to risks and uncertainties, many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update, except as required by U.S. federal securities laws, any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events. No assurances can be made that the parties will successfully complete the transactions described in this press release. Contact Information Communications [email protected] Investor Relations [email protected]
Yahoo
8 minutes ago
- Yahoo
Anthropic Co-founder Says AGI 'Possible' By 2028 But 'Transformative AI' Will Have To Pass The 'Economic Turing Test'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Anthropic co-founder Ben Mann says true "transformative AI" will arrive only after systems ace what he calls the "economic Turing test." What Happened: Mann, in a recent appearance on the 'No Priors' podcast, defined the 'economic Turing test' as a workplace trial that forces hiring managers to choose between a month-long contractor and an AI agent for the same job. Passing the test would mark "when things start to get really interesting from a societal and cultural standpoint," Mann noted. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Mann's yardstick swaps laboratory benchmarks for a market basket covering "50% of economically valuable tasks." Each human supervisor would "hire an agent" to perform the work. If, at the end of the month, the manager prefers the machine, "then it passed," he does warn that the exercise has its limitations. "Interviews are only a poor approximation of real-world job performance," he observed, dismissing current testing measures as limited and too theoretical. Anthropic has already run its Claude models through internal interviews and found them "extremely good," though Mann conceded that the formal trial "hasn't started" and might not come until after the firm's next release cycle. He pegged 2028 as a "quite possible" window for artificial general intelligence but cautioned that precise timelines remain It Matters: Mann's coinage of the phrase 'economic Turing test' builds on the Turing Test, which is a simple method of inquiry in artificial intelligence for determining whether or not a computer is capable of thinking like a human being. OpenAI's ChatGPT 4 became the first AI LLM to pass a two-player Turing test, fooling human conversation partners 54% of the time back in July 2024. GPT-4.5 achieved a 73% success rate in a more formal test in March earlier this year. However, critics have posed several reasons over the years challenging the accuracy of the test in determining the true intelligence of machines. A new Wharton study also found that large language models now create memes humans rate as funnier than the average person's, effectively passing the "meme Turing Test." Anthropic's momentum is accelerating. A March Series E round pushed its valuation to $61.5 billion, positioning the startup backed by Inc. (NASDAQ:AMZN) and Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) as OpenAI's fiercest privately held rival. Read Next: In terms of getting money back, these bank accounts put traditional checking and savings accounts to shame. Maximize saving for your retirement and cut down taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Image via Shutterstock This article Anthropic Co-founder Says AGI 'Possible' By 2028 But 'Transformative AI' Will Have To Pass The 'Economic Turing Test' originally appeared on Sign in to access your portfolio
